MM-302, an antibody drug conjugated liposomal doxorubicin, specifically targets cancer cells that over express the HER2/ErbB2 receptor. This targeted liposomal encapsulation of doxorubicin is designed to allow for the selective uptake of drug into tumor cells while limiting exposure to healthy tissues, such as those of the heart.
This is high level cutting edge molecular science. Only phase I, so don't get TOO excited. Still, these are creative ideas right on the edge of our understanding. The results of phase I will be presented this Tuesday thru Friday. I have a feeling from reading the article that the results will be groundbreaking.
I do not expect the results to have a very great effect on the PPS, but a good indicator of what the future of Merrimack will be. Of the entire market, biotech is the place to be.
All those you cite in your rant have English skills far in excess of your own. Shut up Smith.
There is a new Italian snow tire. Shaped like Italy, the boot and heel design really dig in. Dago through rain, dago through ice, dago through snow, and when dago flat, dago #$%$ #$%$ #$%$!
Yup. The fruitcake is ruining the message board.
And you, profiteer, are egging him on. Shut up both of you.
One discrepancy though. asfxprofiteer on the ASFX.PK board in 2009 never got rattled. Mensa gets rattled. DrSteven51 would get arrogant and silent, but never rattled. Maybe Mensa is not a pumper, but I had to test him.
Ha! I can fart in 7 notes. I can play happy birthday with farts. FART fart fart FART fart!
But really, it is obvious that Mensa is a pro. A hired gun. A pumper if there ever was one. He is good for MACK now, until his target price is attained. Then he will disappear forever. Like a ghost.
Amazing number of posts. It reminds me of DrSteven51 on the MJNA board last year, or asfxprofiteer on the ASFX board in 2009. Polished professional delivery, pumping on a dozen boards, 24/7 without respite.